MedImmune Inc. has received approval from the Turkishminister of health to market the polyclonal antibody productCytoGam for preventing cytomegalovirus (CMV) diseaseassociated with kidney transplants.
MedImmune (NASDAQ:MEDI) will distribute CytoGam inTurkey through Biocer Ltd.
MedImmune (NASDAQ:MEDI) launched CytoGam in the U.S. inNovember 1991 and is currently awaiting regulatory approvalto begin marketing in Canada, Poland, the Czech Republic,Hungary, Austria, Romania and Saudi Arabia. MedImmune ofGaithersburg, Md., filed an amendment to its U.S. productlicense application (PLA) in June 1992 seeking an indication foruse of CytoGam in all solid organs.
(c) 1997 American Health Consultants. All rights reserved.